Imatinib (Gleevec, Novartis, Basel, Switzerland) revolutionized therapeutic strategies for chronic myeloid leukemia (CML) through targeting the BCR-ABL fusion protein, which drives constitutive tyrosine kinase activity and in turn the malignant behaviors of leukemic cells [7]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.